NICM
JANX icon

Neo Ivy Capital Management’s Janux Therapeutics JANX Stock Holding History

Neo Ivy Capital Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,674
Closed -$940K – 340
2024
Q3 		$940K Buy
+20,674
New +$899K 0.3% 137

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Neo Ivy Capital Management's JANX Position: Q4 2024 in Review

Neo Ivy Capital Management sold out of Janux Therapeutics (JANX) in Q4 2024, closing a stake of 20,674 shares — an estimated $940K sold.

Neo Ivy Capital Management first reported a position in JANX in Q3 2024 and held it in 1 quarter. The position peaked at $940K in Q3 2024. 216 funds tracked by Wall St. Rank hold JANX as of Q4 2024.

  • Neo Ivy Capital Management reported no remaining Janux Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Neo Ivy Capital Management sold 20,674 Janux Therapeutics shares in Q4 2024, an estimated $940K.
  • Neo Ivy Capital Management first reported a position in Janux Therapeutics in Q3 2024 and held it in 1 quarter.
  • Neo Ivy Capital Management's Janux Therapeutics position peaked at $940K in Q3 2024.
  • 216 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2024.

Based on Neo Ivy Capital Management's 13F filing for Q4 2024, filed 18 Feb 2025.